SE0201863D0 - Cell penetrating peptides - Google Patents

Cell penetrating peptides

Info

Publication number
SE0201863D0
SE0201863D0 SE0201863A SE0201863A SE0201863D0 SE 0201863 D0 SE0201863 D0 SE 0201863D0 SE 0201863 A SE0201863 A SE 0201863A SE 0201863 A SE0201863 A SE 0201863A SE 0201863 D0 SE0201863 D0 SE 0201863D0
Authority
SE
Sweden
Prior art keywords
cpp
present
relates
predicting
verifying
Prior art date
Application number
SE0201863A
Other languages
Unknown language ( )
English (en)
Inventor
Margus Pooga
Madis Metsis
Priit Kogerman
Andreas Valkna
Anne Meikas
Samir El-Andaloussi
Maria Lindgren
Astrid Graeslund
Goeran Eriksson
Claes Goeran Oestensson
Metka Budihna
Matjaz Zorko
Anna Elmquist
Ursel Soomets
Pontus Lundberg
Uelo Langel
Kalle Kilk
Mattias Haellbrink
Original Assignee
Cepep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Ab filed Critical Cepep Ab
Priority to SE0201863A priority Critical patent/SE0201863D0/
Publication of SE0201863D0 publication Critical patent/SE0201863D0/
Priority to PCT/IB2003/003163 priority patent/WO2003106491A2/en
Priority to EP03760107A priority patent/EP1516184B1/en
Priority to AT03760107T priority patent/ATE368853T1/de
Priority to DE60315296T priority patent/DE60315296T2/de
Priority to HK05108432.4A priority patent/HK1078130B/en
Priority to JP2004513322A priority patent/JP4503435B2/ja
Priority to AU2003253125A priority patent/AU2003253125A1/en
Priority to US10/517,079 priority patent/US20080234183A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
SE0201863A 2002-06-18 2002-06-18 Cell penetrating peptides SE0201863D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides
PCT/IB2003/003163 WO2003106491A2 (en) 2002-06-18 2003-06-18 Cell penetrating peptides
EP03760107A EP1516184B1 (en) 2002-06-18 2003-06-18 Cell-selective delivery system
AT03760107T ATE368853T1 (de) 2002-06-18 2003-06-18 Zell-selektives abgabe system
DE60315296T DE60315296T2 (de) 2002-06-18 2003-06-18 Zell-selektives Abgabe System
HK05108432.4A HK1078130B (en) 2002-06-18 2003-06-18 Cell-selective delivery system
JP2004513322A JP4503435B2 (ja) 2002-06-18 2003-06-18 細胞選択的送達系
AU2003253125A AU2003253125A1 (en) 2002-06-18 2003-06-18 Cell penetrating peptides
US10/517,079 US20080234183A1 (en) 2002-06-18 2003-06-18 Cell Penetrating Peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides
US39178802P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
SE0201863D0 true SE0201863D0 (en) 2002-06-18

Family

ID=29738564

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201863A SE0201863D0 (en) 2002-06-18 2002-06-18 Cell penetrating peptides

Country Status (8)

Country Link
US (1) US20080234183A1 (enExample)
EP (1) EP1516184B1 (enExample)
JP (1) JP4503435B2 (enExample)
AT (1) ATE368853T1 (enExample)
AU (1) AU2003253125A1 (enExample)
DE (1) DE60315296T2 (enExample)
SE (1) SE0201863D0 (enExample)
WO (1) WO2003106491A2 (enExample)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
AU2001257169C1 (en) * 2000-04-21 2011-06-16 Tufts Medical Center, Inc. G-protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
EP1653989B1 (fr) 2003-08-14 2009-07-15 Diatos Composition anti-bacterienne plus particulierement contre les bacteries gram negatif comprenent un peptide et un agent anti-bacterien avantageusement hydrophobe
EP1512696A1 (en) * 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
PT2332968T (pt) 2003-11-05 2016-08-17 Harvard College Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
CA2565685A1 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
CN101072566B (zh) * 2004-11-03 2012-05-16 为人技术株式会社 用于经皮给药的药物组合物
CA2586344C (en) * 2004-11-04 2013-05-28 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
FR2877946B1 (fr) 2004-11-12 2011-02-11 Commissariat Energie Atomique Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet
CA2593956A1 (en) 2004-12-22 2006-06-29 Lipopeptide Ab Agents inhibiting the cathelin-like protein cap18/ll-37
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
ES2609520T3 (es) 2005-10-04 2017-04-20 Soligenix, Inc. Péptidos novedosos para tratar y prevenir trastornos relacionados con el sistema inmunitario, incluyendo el tratamiento y la prevención de infecciones modulando la inmunidad innata
JP5093100B2 (ja) * 2006-03-13 2012-12-05 学校法人慶應義塾 インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤
US8642559B2 (en) * 2006-10-13 2014-02-04 University Of Southern California C-terminal domain truncation of mGluR1α by calpain and uses thereof
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
AU2008211854C1 (en) * 2007-01-29 2014-01-23 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
DE102007008596B4 (de) * 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
AU2008295509A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
WO2009099677A2 (en) 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
EP2090584A1 (en) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
DE102009043743B4 (de) 2009-03-13 2016-10-13 Friedrich-Schiller-Universität Jena Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
EP2250278B1 (en) * 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
WO2009120993A2 (en) * 2008-03-28 2009-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof
JP5763525B2 (ja) * 2008-05-07 2015-08-12 サーモディクス，インコーポレイティド 粒子からの核酸複合体の送達
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP2285970A4 (en) * 2008-06-03 2011-10-12 Aileron Therapeutics Inc COMPOSITIONS AND METHODS FOR REINFORCING THE CELL TRANSPORT OF BIOMOLECULES
US8575305B2 (en) 2008-06-04 2013-11-05 Medical Research Council Cell penetrating peptides
ES2613866T3 (es) 2008-06-12 2017-05-26 Centre For Addiction And Mental Health Composiciones y métodos para modular la interacción y la función del receptor de dopamina D1-D2
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
US20140248296A1 (en) * 2008-10-16 2014-09-04 Kathleen Cogan Farinas Sustained drug delivery system
WO2010053547A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr5 receptor compounds
US20110294738A1 (en) * 2008-11-04 2011-12-01 Yong Ren Pthr1 receptor compounds
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
AU2009329893A1 (en) * 2008-12-23 2011-06-30 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2010085665A2 (en) * 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010115286A1 (en) * 2009-04-09 2010-10-14 Centre For Addiction And Mental Health Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
GB0910620D0 (en) 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9808504B2 (en) * 2009-09-22 2017-11-07 Yale University Immunogenic epitopes as targets for universal cancer vaccines
EP3252068B1 (en) 2009-10-12 2025-07-02 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011072292A2 (en) * 2009-12-11 2011-06-16 Dicerna Pharmaceuticals, Inc. Phase changing formulations of rna and rna derivatives
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ， インコーポレイテッド アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
US9540680B2 (en) * 2010-06-07 2017-01-10 The Trustees Of The University Of Pennsylvania Transcriptome in vivo analysis
NZ704192A (en) * 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CN102947444A (zh) * 2010-06-23 2013-02-27 帷幄生物技术公司 用于治疗心血管疾病的非遗传修饰性重编程细胞的组合物和方法
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US8791121B2 (en) 2010-08-12 2014-07-29 New York University Oligooxopiperazines and methods of making and using them
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
RU2013110876A (ru) * 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9518105B2 (en) * 2010-12-08 2016-12-13 The Research Foundation For The State University Of New York Polypeptides derived from calcitonin receptors and methods of use
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
AU2012239880B2 (en) 2011-04-08 2017-06-15 Tufts Medical Center, Inc. Pepducin design and use
US9880151B2 (en) * 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EP2715291A4 (en) 2011-05-31 2015-10-21 Airware Inc NON-DISPERSIVE GAS SENSORS WITH ABSORPTION INFRARED ABSORPTION (NDIR)
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
EP2537858A1 (en) 2011-06-20 2012-12-26 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013030569A2 (en) 2011-08-30 2013-03-07 Michael John Gait Peptides
WO2013040015A2 (en) * 2011-09-13 2013-03-21 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9259483B2 (en) 2011-11-24 2016-02-16 Positec Power Tools (Suzhou) Co Ltd Peptide sequence design and use thereof for peptide-mediated siRNA delivery
CN102532565B (zh) * 2011-12-19 2013-08-28 上海交通大学 可降解亚胺类聚阳离子及其合成方法、纳米颗粒
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2814821B1 (en) 2012-02-16 2018-04-25 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
KR20150032265A (ko) * 2012-06-26 2015-03-25 에프. 호프만-라 로슈 아게 세포 침투성 펩티드 및 세포 침투성 펩티드의 식별 방법
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
EP2708235A1 (en) 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptide antagonists of the vasopressin-2 receptor
EP2920197B1 (en) 2012-09-26 2021-03-17 President and Fellows of Harvard College Proline-locked stapled peptides and uses thereof
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
RU2015123315A (ru) 2012-11-25 2017-01-10 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Пептиды, стимулирующие подкожный адипогенез
ITMI20122263A1 (it) * 2012-12-28 2014-06-29 Azienda Ospedaliero Universitaria Di Parma Nuovi peptidi cationici ciclici ad attività antimicrobica
EP2991665A4 (en) 2013-03-13 2016-11-09 Harvard College STACKED AND GRAFTED POLYPEPTIDES AND USES THEREOF
EP2784094A1 (en) 2013-03-28 2014-10-01 Commissariat A L'energie Atomique Et Aux Energies Alternatives New uranium-chelating peptides derived from EF-hand calcium-binding motif useful for uranium biodetection and biodecontamination
EA201591760A1 (ru) 2013-03-28 2016-02-29 Коммиссариат А Л'Энержи Атомик Э О Энержи Альтернатив Новые уран-хелатирующие пептиды, происходящие из кальций-связывающего мотива ef-hand, пригодные для биодетекции и биодеконтаминации урана
KR20160019547A (ko) 2013-06-14 2016-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 안정화된 폴리펩티드 인슐린 수용체 조절제
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN105659088A (zh) * 2013-06-26 2016-06-08 菲洛吉卡有限公司 用于监测肽的细胞运输的方法
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP2842566A1 (en) 2013-09-03 2015-03-04 Centre National De La Recherche Scientifique Use of arpin a new inhibitor of the arp2/3 complex for the diagnosis and treatment of diseases
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
JP6493216B2 (ja) * 2013-11-05 2019-04-03 味の素株式会社 ペプチドヒドラジド、ペプチドアミド及びペプチドチオエステルの製造方法
EP3086813B9 (en) * 2013-12-23 2023-09-27 Covalab Mtg substrates for covalent conjugation of compounds
WO2015105957A1 (en) * 2014-01-08 2015-07-16 Shriners Hospitals For Children Pten antagonist peptides and methods of using the same
WO2015108955A2 (en) * 2014-01-15 2015-07-23 The Board Of Regents Of The University Of Texas System Targeting of pelp1 in cancer therapy
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
EP2905031A1 (en) 2014-02-10 2015-08-12 B Cell Design A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
MX2016013025A (es) 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
CN111620940A (zh) 2014-05-21 2020-09-04 哈佛大学的校长及成员们 Ras抑制肽和其用途
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
PT3388075T (pt) 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
ES2984663T3 (es) 2015-11-13 2024-10-30 Oasis Pharmaceuticals Llc Moduladores del receptor 2 activados por proteasa
US12050215B2 (en) * 2015-11-17 2024-07-30 The Regents Of The University Of Michigan Macromolecular structures and uses thereof
ES2906782T3 (es) * 2016-03-15 2022-04-20 Idp Discovery Pharma S L Péptidos con actividad antineoplásica
GB201607521D0 (en) * 2016-04-29 2016-06-15 Oncolmmunity As Method
EP3484482A4 (en) * 2016-07-15 2020-07-29 The Board of Regents of the University of Oklahoma ANTI-ARID3A TREATMENTS FOR INFLAMMATORY DISORDERS
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
CN110114075B (zh) 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
AU2017373962B2 (en) 2016-12-07 2022-03-31 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
EP3360891B1 (en) 2017-02-14 2022-03-30 Karlsruher Institut für Technologie Cell penetrating peptides of human origin
EP3628047A1 (en) 2017-05-02 2020-04-01 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
KR102095284B1 (ko) * 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
US12337000B2 (en) 2017-07-13 2025-06-24 Michael David FORREST Therapeutic modulators of the reverse mode of ATP synthase
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
WO2019058263A1 (en) * 2017-09-19 2019-03-28 Auckland Uniservices Limited PEPTIDES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF ADIPONECTIN
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3720450A4 (en) * 2017-12-04 2021-07-28 Heat Biologics, Inc. CELL-BASED VACCINE PRODUCTION
EP3784697A4 (en) * 2018-04-27 2022-07-06 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
US12171838B2 (en) 2018-07-02 2024-12-24 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of nucleic acids
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
US20220048953A1 (en) * 2018-09-26 2022-02-17 Kaneka Corporation Cell-penetrating peptide
CA3122200A1 (en) * 2018-12-07 2020-06-11 Oxford University Innovation Limited Linkers
CN118079011A (zh) 2019-02-01 2024-05-28 利兰斯坦福初级大学董事会 用于将核酸递送至肺部的分解性细胞穿透复合物
EP3921329A1 (en) * 2019-02-04 2021-12-15 University of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US12338268B2 (en) * 2019-03-05 2025-06-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating protein aggregation-associated diseases
CN112279921B (zh) 2019-07-11 2025-07-29 厦门大学 用于胞内递送分子的复合物
TWI862641B (zh) * 2019-07-22 2024-11-21 美商第一美膚公司 具有抗老化功效之多肽及其用途
AR119529A1 (es) 2019-08-02 2021-12-22 Idp Discovery Pharma S L Péptidos reguladores de melanocitos
CN121045395A (zh) * 2019-11-22 2025-12-02 阿尔卡梅纳干细胞治疗有限公司 用于去抑制re1沉默转录因子靶基因的组合物和方法
WO2021113434A1 (en) 2019-12-03 2021-06-10 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth
EP4086275A4 (en) 2019-12-31 2024-04-17 Xiamen University Multimerization delivery system for intracellular delivery of molecule
EP3906935A1 (en) 2020-05-06 2021-11-10 Sorbonne Universite Peptides for preventing or treating viral infections
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
EP4281034A1 (en) 2021-01-24 2023-11-29 Forrest, Michael, David Inhibitors of atp synthase - cosmetic and therapeutic uses
US20240182526A1 (en) * 2021-03-31 2024-06-06 University Of Southern California Compositions and methods for modulting inflammatory and degenerative disorder
JP2024513087A (ja) 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
CN115385987B (zh) * 2021-05-19 2024-08-02 中山大学 一种抗鱼类神经坏死病毒的穿膜肽及其应用
KR102504190B1 (ko) * 2021-06-03 2023-02-28 주식회사 레메디 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법
KR102819567B1 (ko) * 2021-11-24 2025-06-13 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
KR102793149B1 (ko) * 2021-11-24 2025-04-09 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
CN114349846B (zh) * 2022-01-07 2023-12-15 天津市泌尿外科研究所 一种人精子膜蛋白or1d2特异性多肽与抗体的制备方法
WO2023181070A1 (en) * 2022-03-23 2023-09-28 Council Of Scientific & Industrial Research PEPTIDE TO TREAT α-SYNUCLEIN AMYLOID BASED DISORDERS
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
CN120641131A (zh) 2022-12-01 2025-09-12 耶鲁大学 用于细胞内有效载荷递送的刺激反应性无痕工程化平台
WO2025172421A1 (en) 2024-02-14 2025-08-21 Astrazeneca Ab Compositions and methods for treatment of huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734827B2 (en) * 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
JP4465109B2 (ja) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
WO2000034308A2 (en) * 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
WO2001097830A1 (en) * 2000-06-22 2001-12-27 Mount Sinai School Of Medicine Modification of mdm2 activity
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
NZ524386A (en) * 2000-08-25 2005-10-28 Aventis Pharma Inc Membrane penetrating peptides and uses thereof
AU2001288025A1 (en) * 2000-09-05 2002-03-22 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
FR2818981A1 (fr) * 2001-01-03 2002-07-05 Synt Em Peptides amphipathiques et leur utilisation pour le transfert de substances d'interet dans les cellules
AU2002240201A1 (en) * 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
DE10390251D2 (de) * 2002-01-27 2004-12-23 Viromics Gmbh Trojanische Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
JP2006514602A (ja) 2006-05-11
HK1078130A1 (en) 2006-03-03
AU2003253125A1 (en) 2003-12-31
US20080234183A1 (en) 2008-09-25
EP1516184A2 (en) 2005-03-23
JP4503435B2 (ja) 2010-07-14
DE60315296D1 (de) 2007-09-13
EP1516184B1 (en) 2007-08-01
WO2003106491A3 (en) 2004-12-23
AU2003253125A8 (en) 2003-12-31
DE60315296T2 (de) 2008-04-17
ATE368853T1 (de) 2007-08-15
WO2003106491A2 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
SE0201863D0 (en) Cell penetrating peptides
IL178515A0 (en) Oligopeptides for reducing elevated blood urea concentration
WO2003072599A3 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2003085086A3 (en) Motif-grafted hybrid polypeptides and uses thereof
WO2003063760A3 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
AU2003240631A1 (en) A t cell subpopulation regulating gut immunity
ATE321782T1 (de) Membrantranslokierendes peptid als wirkstofftransportsystem
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2005049641A3 (en) Surface-located campylobacter jejuni polypeptides
TW200508249A (en) Antibodies for the cancer specific antigen
GB0207644D0 (en) Peptides and their use
MXPA06000661A (es) Npcili (npc3) y metodos de uso del mismo.
TR200100175T2 (tr) Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
EP1511506A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING, TREATING AND DIAGNOSING DIABETES
SE0001530D0 (sv) A reporter protein
EP1801232A4 (en) METHOD FOR SCREENING A TRANSMEMBRANENZYMHEMMSTOFFS
WO2010133806A3 (fr) Peptides marques et leur utilisation pour le dosage d'irap circulant
DE60327263D1 (de) Beta-strang-mimetika
EP1465911A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES, INSULIN RESISTANCE AND DYSLIPIDEMIA
WO2003099209A3 (en) Compositions and methods for screening and identifying anti-hcv agents